<DOC>
	<DOCNO>NCT03055494</DOCNO>
	<brief_summary>This study provide comparison secukinumab placebo respect skin inflammation measure skin exam comparison skin biopsy , adipose tissue blood sample analysis .</brief_summary>
	<brief_title>Study Explore Effect Secukinumab , Compared Placebo , Fat Tissue Skin Plaque Psoriasis Patients</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Written informed consent must obtain assessment perform Clinical diagnosis chronic plaquetype psoriasis least 6 month prior randomization Moderate severe plaque psoriasis define baseline : ≥10 % Body Surface Area ( BSA ) involvement PASI total score ≥12 IGA mod 2011 score ≥3 ( base scale 04 ) Forms diagnose psoriasis chronic plaque psoriasis Medicationinduced medication exacerbate psoriasis Previous exposure secukinumab biologic drug directly target IL17A IL17RA receptor Ongoing use prohibit treatment Pregnant nursing ( lactate ) woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>